There are currently 32 active clinical trials seeking participants for Pulmonary Hypertension research studies. The states with the highest number of trials for Pulmonary Hypertension participants are California, Florida, New York and Ohio.
A Study of Mosliciguat in PH-ILD
NCT06635850
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/11/2025
Locations: Arizona Pulmonary Specialists, Phoenix, Arizona +17 locations
Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Register for Updates
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
NCT06129240
Recruiting
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/30/2025
Locations: Arizona Pulmonary Specialists, Phoenix, Arizona +22 locations
Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates
Study Roles of Heavy Metals and Essential Metal Dyshomeostasis in Pulmonary Arterial Hypertension Patients
NCT04756076
Recruiting
Investigators plan to recruit 50 PAH patients from UofL PAH Clinic, with various degrees of severity (25 intermediate risk patients and 20 high risk patients) and 10 age and gender matched controls. PAH patients are evaluated at least every 6 months by the PAH Clinic and blood/urine samples will be obtained at each office visit. Blood, plasma and urine samples will be used to measure 31 metal levels including heavy metals (cadmium, arsenic, cobalt, lead etc.) and essential metals (calcium, coppe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2025
Locations: University of Louisville Health, Louisville, Kentucky
Conditions: Pulmonary Hypertension, Metal Poison
Register for Updates
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
NCT05937854
Recruiting
The investigators will study whether the drug tadalafil improves shortness of breath in 126 Veterans with Chronic Obstructive Pulmonary Disease (COPD) and high blood pressure in the lungs. The investigators will also assess whether tadalafil improves quality of life, home daily physical activity, exercise endurance, the frequency of acute flares of COPD, blood pressure in the lungs, and lung function. Veterans who enroll in the trial will be allocated by chance to either active tadalafil or an i... Read More
Gender:
ALL
Ages:
Between 35 years and 89 years
Trial Updated:
04/29/2025
Locations: Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado +4 locations
Conditions: Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension, Dyspnea
Register for Updates
Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension
NCT06770023
Recruiting
The purpose of this study is to determine if transseptal extra-corporeal membrane oxygenation (ECMO) can bridge pulmonary hypertension- right heart failure (PH-RVF) patients to lung transplant safely.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/21/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Lung Transplant, Pulmonary Hypertension
Register for Updates
iTONE Trial (exercIse Training in pulmONary hypertEnsion) Exercise Program for Pediatric PH
NCT05442671
Recruiting
Children with pulmonary hypertension (PH) engage in less physical activity than their peers. This is a concern since adult data support exercise as a non-pharmacologic treatment for PH. Despite adult data, therapeutic exercise has not been widely adopted in pediatric PH. Investigators have previously demonstrated that children with PH have less skeletal muscle mass in association with worse exercise performance. Interventions to increase physical activity and skeletal muscle mass may improve exe... Read More
Gender:
ALL
Ages:
Between 8 years and 18 years
Trial Updated:
04/14/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Pulmonary Hypertension
Register for Updates
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
NCT06616974
Recruiting
TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
Gender:
ALL
Ages:
Between 18 years and 83 years
Trial Updated:
04/10/2025
Locations: Birmingham, Birmingham, Alabama +62 locations
Conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Register for Updates
A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)
NCT05201144
Recruiting
Congenital diaphragmatic hernia (CDH) occurs in approximately 1 in 3000 US live births, similar to the incidence seen within the Utah Birth Defects cohort. The diaphragmatic defect compromises lung growth and alters pulmonary vascular development. This is reflected postnatally as respiratory failure, pulmonary hypertension (PH) and overall cardiopulmonary dysfunction, particularly post-repair. Currently, optimal management of post-repair PH remains poorly investigated. Sildenafil citrate is a hi... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/01/2025
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Congenital Diaphragmatic Hernia, Pulmonary Hypertension
Register for Updates
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
NCT04624490
Recruiting
The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.
Gender:
ALL
Ages:
3 years and above
Trial Updated:
04/01/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
Register for Updates
Feasibility of Semaglutide in Advanced Lung Disease
NCT05746039
Recruiting
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1. Are patients with advanced lung disease able to tolerate semaglutide therapy? 2. Are we able to titrate semaglutide therapy to a target weight? Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a bl... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/13/2025
Locations: University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
Conditions: Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Register for Updates
Autologous Stem Cell Transplantation in Patients with Systemic Sclerosis
NCT03630211
Recruiting
The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.
Gender:
ALL
Ages:
Between 8 years and 60 years
Trial Updated:
03/13/2025
Locations: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania +2 locations
Conditions: Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates
Metformin for Pulmonary Hypertension HFpEF
NCT03629340
Recruiting
The main objective of this study is to determine the clinical efficacy of metformin versus placebo and the therapeutic response with regards to functional capacity and hemodynamics in PH-HFpEF.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: UCSF Medical Center, San Francisco, California +1 locations
Conditions: Pulmonary Hypertension, Heart Failure
Register for Updates